COVID-19 Vaccine- Drugs Controller General of India has granted permission to Cipla as the fourth COVID-19 vaccine in India for emergency use as per the provision of the New Drugs and Clinical Trial Rules, 2019 under Drugs and Cosmetics Acts, 1940, a source said.
India on Tuesday opened doors for the fourth COVID-19 vaccine after Mumbai-based pharmaceutical company Cipla got permission from India’s drug regulator DCGI to import the vaccine for emergency use in the country, officials said.
When India is already administering three Coronavirus vaccines; Oxford’s Covishiled, Covaxin from Bharat Biotech, and Sputnik V from Russia in fighting against the Coronavirus, Cipla was added as the fourth vaccine on the list.
This came into notice when Cipla requested the drug regulator to import and market authorization of this dose.
On 27 June, Moderna informed DCGI that the US Government has agreed to grant a certain number of doses of its COVID-19 vaccine COVAX to India. It got approval from the Central Drugs Standard Control Organization (CDSCO) for the vaccines.
Earlier this month Cipla had indicated its plan to fast-track approval to bring COVAX vaccine into India expeditiously, and it has requested the government for indemnification and exemptions from price capping, bridging trials, and basic customs duty. The Mumbai-based company has not named the vaccine yet.
India became the first country to reach the maximum number of vaccinations in the world. It is expected, India will complete the vaccination by the end of 2021. With these four effective vaccines, India will boost the vaccination and is expected to vaccinate the entire population by the end of december.
